Proqr Therapeutics N V (PRQR) Stock
Clinical biotech developing RNA therapies for rare diseases. Here's the price, business snapshot, and what's worth knowing about Proqr Therapeutics N V in June 2026.
ProQR Therapeutics NV is a clinical-stage biotechnology company developing RNA-based therapies for rare genetic diseases. The firm is known for applying antisense oligonucleotide and RNA editing technologies to tackle disorders where correcting or modulating gene expression could alter disease course, with a focus on inherited retinal diseases and certain respiratory or systemic genetic conditions. As a small-cap, research-driven company, ProQR’s value is closely linked to clinical trial results, regulatory decisions and potential partnerships or licensing deals. Investors should expect volatility typical of biotech stocks — news flow from trials can move the share price sharply, and the company may need to raise capital, which can dilute existing shareholders. For those studying the stock, key considerations are the strength of clinical data, intellectual property position, cash runway and management’s track record. This information is educational and not investment advice; biotech investing carries higher risk and is generally more suitable for investors comfortable with uncertain outcomes.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying PROQR Therapeutics stock with a target price of $7.93, indicating strong growth potential.
Financial Health
PROQR Therapeutics has modest revenue and cash flow, but its financial indicators suggest average performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring PRQR
Beyond Vaccines: The mRNA Revolution
BioNTech's strong vaccine sales are fueling its expansion into new medical fields, particularly cancer treatment. This strategic shift highlights a broader investment opportunity in companies pioneering the next wave of mRNA-based therapies.
Published: 5 August 2025
Explore BasketWhy You’ll Want to Watch This Stock
RNA Therapy Platform
ProQR’s RNA-based approach aims to correct gene expression, a promising scientific route, though clinical success is uncertain and outcomes can vary.
Catalysts To Watch
Clinical readouts, regulatory updates and partnership deals can materially affect value; such events often drive sharp share-price moves.
Risk And Opportunity
Small-cap biotech investing can offer high upside if trials succeed, but carries higher regulatory, commercial and financing risks — suitability depends on investor risk tolerance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
